GO
Loading...

Seattle Genetics CEO on ADCETRIS Drug For Hodgkins

Tuesday, 5 Jun 2012 | 6:45 PM ET

Clay Siegall, Seattle Genetics president & CEO, discusses his company's latest drug developments for non-hodgkins lymphoma and hodgkins lymphoma, and its opportunity to be a "$1 billion plus product on its own."